Laboratory abnormalities resulting from treatment include elevated ALT and hematuria, of which periodic monitoring of hepatic function and hematology is recommended.
Laboratory abnormalities resulting from treatment include elevated alanine transaminase (ALT) and hematuria. Periodic monitoring of hepatic function and hematology is recommended.